Applied Therapeutics reports Q3 EPS (47c), consensus (26c)

“We have continued to make progress across our late-stage pipeline and have several key regulatory and clinical inflection points expected later this quarter and in early 2024,” said Shoshana Shendelman, PhD, Founder, Chief Executive Officer, and Chair of the Board. “We are working expeditiously to submit our regulatory filings for govorestat for the treatment of Classic Galactosemia in both the U.S. and in Europe and look forward to providing updates as those submissions occur. In tandem, we are soon approaching Phase 3 readouts for our ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy and our INSPIRE Trial of AT-007 trial in Sorbitol Dehydrogenase Deficiency, which are expected in 4Q23 and in 1Q24, respectively.”